|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:valsartan
gptkb:sacubitril
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
C09DX04
|
|
gptkbp:brand
|
gptkb:sacubitril/valsartan
|
|
gptkbp:clinicalTrialPhase
|
gptkb:PARADIGM-HF
|
|
gptkbp:contraindication
|
pregnancy
history of angioedema
concomitant use with ACE inhibitors
|
|
gptkbp:drugClass
|
angiotensin receptor neprilysin inhibitor
|
|
gptkbp:eliminationRoute
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
24/26 mg
49/51 mg
97/103 mg
|
|
gptkbp:halfLife
|
sacubitril: 1.4 h, valsartan: 9.9 h
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Entresto
|
|
gptkbp:improves
|
cardiovascular outcomes in heart failure
|
|
gptkbp:indication
|
reduced ejection fraction heart failure
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
inhibits neprilysin and blocks angiotensin II receptor
|
|
gptkbp:notRecommendedFor
|
severe hepatic impairment
concomitant use with aliskiren in diabetics
|
|
gptkbp:patent
|
gptkb:Novartis
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyWarning
|
may cause fetal harm
|
|
gptkbp:prescribes
|
adults with chronic heart failure
pediatric heart failure (in some regions)
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:reduces
|
hospitalization for heart failure
risk of cardiovascular death
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
cough
hypotension
renal impairment
hyperkalemia
|
|
gptkbp:storage
|
store at room temperature
|
|
gptkbp:usedFor
|
heart failure
|
|
gptkbp:bfsParent
|
gptkb:Novartis
|
|
gptkbp:bfsLayer
|
4
|